Member Info for Moneymunch

SFX-01 was selected for Covid-19 patient trials because it is a potent activator of the Nrf2 pathway which regulates the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation, but SFX-01 is also a potent activator of the STAT3 pathway and the recent discovery that STAT3 is the "key to immune system inflammation" which must significantly increase SFX-01's potential and chances in becoming an effective treatment for multiple disease targets, including Covid-19.

STAT3 was the focus of SFX-01's phase 2 breast cancer trials, where results were outstanding and life changing for some patients, phase 2b patient trials are in the planning with Manchester University and news on their status is expected soon, and so given SFX-01's dual activation of these two key pathways and SFX-01's panacea potential, the interest from Big Pharma presumably must be highly significant, which can only add to the chances of an early JV commercil partnership and/or strategic investor imho.....Gla....News from the new CEO at anytime. ;-)

Health

October 1, 2020

Key to immune system inflammation discovered

Hudson Institute scientists have discovered the key to how cells turn on inflammation and fight infection, providing the knowledge to potentially reduce or stop destructive inflammation in future.

The finding comes as the world finds itself in the grip of the SARS-CoV-2 viral pandemic, where raging inflammation caused by the body’s overwhelming immune response in some individuals can lead to death and debilitating ongoing symptoms.

“Inflammation arising from our own immune system response is now recognised as an underlying component of almost every disease,” said A/Prof Ashley Mansell co-author of the study published in Nature Communication. “This includes heart, lung, brain and infectious diseases, cancer, diabetes and chronic kidney, liver and autoimmune diseases.

“If we could reduce dysfunctional or exaggerated inflammation, we would reduce the suffering associated with these severe inflammatory diseases.

“Understanding how cells turn on inflammation provides the building blocks to do this, by potentially targeting these pathways to restrain or stop inflammation attacking the body.”

Presumably no shortage of patients for SFX-01's Covid-19 patient trials, as SFX-01 will be administered to patients with pneumonia and acute respiratory infections regardless of testing positive for Covid-19 , and so early reporting could be very likely, and SFX-01's commercial potential could be huge if positive indications are observed. Gla ;-)

SFX-01 treatment for Acute Respiratory Infections (STAR-Covid19)

A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in patients with community acquired pneumonia and suspected or confirmed SARS-CoV-2 infection

"for the avoidance of doubt, this trial permits inclusion of patients presenting with acute respiratory infections whether or not the test for SARS-CoV-2 is positive. Patients can be randomised to the study while awaiting the results of the test for SARS-CoV-2."

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003486-19/GB

Cheers opulentia, and wish I'd hung on to all my shares I had way back when but grabbed a modest amount today, I'm heavily invested in EVG at the moment but will put more in here if I get the chance when EVG takes off. .....today's certainly suggests that some big news might be coming, and good news on Bhukia would see this sky rocket. Gl :-)

Hardly surprising that SFX-01 will be administered to patients with pneumonia regardless of testing positive for Covid-19 or not....could be massive if proved effective. Gla ;-)

Nearly five times more people dying of flu and pneumonia than coronavirus

12 Aug 2020

Read more: https://metro.co.uk/2020/08/12/nearly-five-times-people-dying-flu-pneumonia-coronavirus-13118709/?ito=cbshare

Very interesting and quite an amazing turn around....the next hearing date for the Bhukia gold prospect is 24/11/20.....but it certainly looks like an out of court settlement/agreement has been made/reached given the surge in sp. Gla ;-)

Rajasthan High Court Principal Seat Jodhpur
Case DetailsCase Type : CW
Filing Number: 36276/2018Filing Date: 01-09-2018
Registration Number: 13521/2018Registration Date: 05-09-2018
CNR Number: RJHC01-060720-2018

Case Status
First Hearing Date
:

Next Hearing Date
: 24th November 2020

Stage of Case
: ---

Coram
: 1634VIJAY BISHNOI
Bench
: Single Bench
State
: RAJASTHAN
District
: Banswara
Judicial
: WRIT
Causelist Name
: Daily

Petitioner and Advocate1) METAL MINING INDIA PVT. LTD.

Advocate- VIKAS BALIA,PRAMOD VYASPRAMOD VYAS ,DINESH PAL SINGH CHARAN,ASHOK CHOUDHARY,PRAMOD VYAS

Respondent and Advocate1) STATE OF RAJASTHAN

Advocate - SANDEEP SHAH
2) DIRECTOR

Advocate-SANDEEP SHAH
3) UNION OF INDIA

Acts
Under Act(s) Under Section(s)
Other Acts 226

IA Details
IA Number Party Date of Filing Next Date IA Status
APPLW/1/2019 METAL MINING INDIA PVT. LTD.
STATE OF RAJASTHAN
04-11-2019 -- Pending
Sub Matters
Case Number : CMS/13534/2018

2 x 250k trades just gone through at 14.03p...!!!!???? Gla ;-)

Accumulation on the cheap, as i can't see how they would be sells at that price and it was confirmed earlier on Advfn that all the 14p trades were buys!!!?????

courtesy of smackeraim;

I can get a quote for 150k at 14p.. those are buys..

http://prntscr.com/v2d0j9

Evgen initially stated that the Covid-19 trial would be conducted at up to 6 hospitals in Scotland and the North of England, although University of Dundee's press release stated "from hospitas across the UK" , and so maybe could include Bolton, or maybe even make SFX-01 available to her, given her high profile position....best wishes to her regardless.

16/6/20

The study will recruit up to 300 volunteers from hospitals across the UK, with patients offered the chance to participate immediately after their diagnosis. Half the group will receive SFX-01 in addition to standard hospital care while the other half will receive a placebo. Results are expected by the end of the year.

https://www.dundee.ac.uk/stories/clinical-trial-potential-covid-19-treatment

Could be offered SFX-01 as detailed on clinical trial link posted by Timbo earlier, whereby SFX-01 will be administered to patients with pneumonia regardless if they've tested positive for Covid-19 or not....and so high profile coverage possible if she makes speedy recovery. Gla and gl to her...:-)

Labour MP Yasmin Quereshi has been hospitalized after testing positive for the coronavirus. 

UK Shadow International Development Minister Yasmin Qureshi has been admitted to hospital with pneumonia after testing positive for COVID-19.

The Labour member of parliament for Bolton South East said she had been self-isolating at home with her family.

Qureshi said in a statement that "I began to feel much worse and on Saturday I was admitted to the Royal Bolton Hospital with pneumonia."

It's also extremely interesting and exciting to note from the Cinical trial link that SFX 01 will be administered to patient with pneumonia regardless of being tested positive for Covid-19....SFX-01 was selected for Covid-19 patient trials because academia and industry believe , because of its potent Nrf2 activation, and anti-inflammatory properties, it beneficial in treating ARDS, acute respiratory distress syndrome, which as well as severe pneumonia is the reason Covid-19 can be so deadly and chronic for many. This means potentially, SFX-01 could be of benefit not only to Covid-19 but also ARDS and pneumonia, long after Covid-19 is hopefully defeated...and also suggests that early reporting on the trials would be highly likely if those with pneumonia are the focus....Gla ;-)

Courtesy of timbo from Advfn....official confirmation of SFX-01's Covid-19 clinical patient trials....On and UP!!! ;-)

Here's the link to the protocol for the Dundee COVID study

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003486-19/GB

I see the primary assessment is based on an ordinal scale and the main requirement for entry is pneumonia and a COVID test (which does not have to be positive)

It is Randomised placebo, controlled double, blind (all good) with 300 patients

If there's any substance behind the substantial share transfer/accumulation that appears to have been in progress over the last several months, then the amount of shares available in free float could be incredibly low imho.....and so any increased volume and demand for shares should see this fly....and long overdue as we continue to await an update on proceedings. Gl ;-)

Looking good and a very nice way to start a Monday morning......Excitement building!!! Gl ;-)

Contrary to the opinion of some, I reckon SFX-01's dual activation of STAT3 and NRF2, makes it a very strong candidate to treat Covid-19 and ARDS judging by the number of high profile research papers recently published, and no doubt the very reason why it was selected for Covid-19 patient trials from over 130 drug application candidates by LifeArc...Gla holders, confirmation that the trials are underway will be very well received and so a very exciting period ahead, in anticipation. :-)

“It is crucial to understand the most appropriate context for introducing an anti-inflammatory therapy to complement an antiviral therapy. Such therapy must control inflammation without altering the ability of the host to mount an efficient adaptive immune response against the virus.

We propose that boosting endogenous cellular defenses by targeting the cytoprotective transcription factor Nrf2 (gene name NFE2L2) will promote the resolution of COVID-19 associated inflammation and also restore redox homeostasis and facilitate tissue repair.

The isothiocyanate sulforaphane (SFN) is the most potent naturally occurring NRF2 activator, with well-documented antioxidant and anti-inflammatory effects. The high bioavailability of SFN makes it an excellent candidate for alleviating excessive anti-inflammatory responses and protecting the lungs.

Interesting tweet from Pro Dillon at University of Dundee, who has had SFX-01 under evaluation for clinical trials for NASH since December 2019.....maybe news could be close. Gla ;-)

John Dillon Retweeted
Journal of Hepatology
@JHepatology
·
Oct 15
Reliability of hepatopathologists’ liver #biopsy evaluation using currently accepted criteria is suboptimal and has major implications for #NASH clinical trials.

http://bit.ly/31s8nvK

........................

5/12/19

Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it has entered into a Memorandum of Understanding with the The University of Dundee ("The University") to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis ("NASH") and liver fibrosis. Evgen has agreed to supply SFX-01 to support a potential future clinical trial led by John Dillon, Professor of Hepatology and Gastrenterology in the University's School of Medicine.

With the assistance of Evgen, Professor Dillon will lead the process to secure appropriate grant funding and obtain clinical trial regulatory approval. The intention is to utilise advanced MRI scanning technology to investigate whether SFX-01 can reverse the hallmarks of NASH in a proof-of-concept clinical trial. Clinical data arising from a successful trial will support subsequent development, regulatory approval and commercialisation of SFX-01 in NASH and liver fibrosis. Evgen will be granted an option to the clinical data on fair commercial terms to enable it to advance development and commercialisation.

Non-alcoholic fatty liver disease ("NAFLD") is now regarded as the most common liver condition in the developed world, affecting up to 30% of the general population. NAFLD represents a spectrum of phenotypes ranging from simple steatosis (fatty infiltration), through NASH to cirrhosis. Approximately 30% of adults in the general population have NAFLD, and 10%-20% of these have NASH. Amongst patients with NASH, 20-30% are at risk of developing cirrhosis and subsequently dying from end-stage liver disease within 20 years. In view of the tens of thousands of individuals who are likely to develop NASH in the next decade, it is clear that this disease will represent a major burden to healthcare in the UK.

Professor John Dillon and colleagues have previously published research that showed that drug-induced activation of the Nrf2 pathway could reverse insulin resistance, suppress hepatic steatosis, and mitigated against NASH and liver fibrosis. On this basis, Professor John Dillon approached Evgen, the developer of SFX-01, a development stage drug that is known to activate the Nrf2 pathway and has demonstrated excellent safety and tolerability in previous clinical trials.

John Dillon, Professor of Hepatology and Gastrenterology at the University of Dundee's the School of Medicine said: "We are delighted that Evgen will support our plans to

This is one of the drugs Trump was on, the US bought up the entire world supplies a few months back when early observations suggested Remdesivir might a have a therapeutic benefit.

Financial Times

@FinancialTimes

Breaking News: The Covid-19 treatment remdesivir has no substantial effect on a patient’s chances of survival, a clinical trial by the World Health Organization has found

https://on.ft.com/319YsKh

Some chunky late buys in after close at 13.75p....All bodes well for Monday...Gla ;-)

Looks like a nice UPward surge into close is definitely on the cards....Gla ;-)))

On and UP!!! ;-)

Scottish numbers: Continue to rise dramatically and so surely news that SFX-01's Covid-19 patient trials are underway is imminent.

16 October 2020

Summary

1,196 new cases of COVID-19 reported; this is 16.9%* of newly tested individuals

9 new reported death(s) of people who have tested positive

58 people were in intensive care yesterday with recently confirmed COVID-19

629 people were in hospital yesterday with recently confirmed COVID-19

21,057 new tests for COVID-19 that reported results

.......................

Scottish numbers:

30 September 2020

640 new cases of COVID-19 reported; this is 10.3% of newly tested individuals.

7 new reported death(s) of people who have tested positive

15 people were in intensive care yesterday with recently confirmed COVID-19.

137 people were in hospital yesterday with recently confirmed COVID-19.

15,629 new tests for COVID-19 that reported results.

Perhaps the biggest piece of near term news, which has been overlooked , would be the 20 year patent extension.....confirmation news would be massive and would add significant UPside imho....Gla ;-)

15/6/20

INTELLECTUAL PROPERTY UPDATE

Our IP portfolio continues to be strengthened with a number of key patents being granted. The current status of the intellectual property portfolio is as follows:

-- From the "parent" patent family entitled "Stabilised Sulforaphane" patents are granted in Australia, Canada, EU, US, Japan and Hong Kong.

-- The principal manufacturing patent application, entitled "Methods of Synthesising Sulforaphane" is granted in Australia, China, Europe, Japan and further applications are pending in Brazil, Canada, US and India.

-- A second manufacturing patent which is directed to methods of isolating and purifying sulforaphane or analogues from natural sources has been granted in Europe, US, Japan and China.

-- The patent application providing protection around novel analogues based on sulforaphane, and entitled "Sulforaphane-Derived Compounds" is granted in Australia, China, Europe, Japan and the US and pending in Canada.

During the year composition of matter SFX-01 patents were granted both in Japan and Europe with a product claim for a complex of sulforaphane and alpha-cyclodextrin. The Group has long held broad compositional patent protection in the United States since patent grant in 2011 and in Canada since grant in 2014.

Furthermore, new composition of matter filings have been made which, if successful, would add a further 20 years of patent life to the key patent family.